Get the Stockscreener App
66.64
2.00%
-1.36
After Hours:
66.64
Bridgebio Pharma Inc stock is traded at $66.64, with a volume of 2.74M.
It is down -2.00% in the last 24 hours and up +0.77% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$68.00
Open:
$67.5
24h Volume:
2.74M
Relative Volume:
1.11
Market Cap:
$13.05B
Revenue:
$579.96M
Net Income/Loss:
$-729.89M
P/E Ratio:
-17.79
EPS:
-3.7459
Net Cash Flow:
$-452.02M
1W Performance:
-1.54%
1M Performance:
+0.77%
6M Performance:
-11.96%
1Y Performance:
+61.98%
1-Day Range:
$65.83
$67.96
1-Week Range:
$65.83
$69.42
52-Week Range:
$39.65
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
66.64 | 13.32B | 579.96M | -729.89M | -452.02M | -3.7459 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | RBC Capital Mkts | Outperform |
| Mar-10-26 | Initiated | William Blair | Outperform |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Initiated | Morgan Stanley | Overweight |
| Dec-11-25 | Initiated | Bernstein | Outperform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jul-09-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
Mizuho Cuts Price Target on BridgeBio Pharma to $96 From $106, Keeps Outperform Rating - marketscreener.com
BBIO (NASDAQ) Form 144 shows proposed sale of 83,088 shares and RSUs - Stock Titan
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Cuts Target Price to $96 - Moomoo
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Exploring A Potential 53.76% Upside - DirectorsTalk Interviews
The Technical Signals Behind (BBIO) That Institutions Follow - Stock Traders Daily
Monashee Investment Management LLC Sells 100,000 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $101 - Moomoo
Dksh Management Ltd. Enters Distribution Partnership with Bridgebio Pharma, Inc. to Support Regulatory Evaluation and Potential Patient Access to Transthyretin Stabilizer for Attr-Cm in Australia, Singapore, South Korea, and Taiwan - marketscreener.com
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma, Inc. $BBIO Shares Acquired by GW&K Investment Management LLC - MarketBeat
BridgeBio Pharma, Inc. $BBIO Position Lifted by Franklin Resources Inc. - MarketBeat
Axiom Investors LLC DE Has $15.87 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Raymond James downgrades BridgeBio Pharma (BBIO) - MSN
TD Asset Management Inc Boosts Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma Insider Sold Shares Worth $5,413,289, According to a Recent SEC Filing - marketscreener.com
BridgeBio Pharma CEO Neil Kumar sells $5.4m in company stock By Investing.com - Investing.com South Africa
BridgeBio Pharma CEO Neil Kumar sells $5.4m in company stock - Investing.com Australia
BridgeBio Pharma(BBIO.US) Officer Sells US$5.41 Million in Common Stock - Moomoo
BridgeBio Pharma (BBIO) CEO’s family trusts sell 80,000 shares under 10b5-1 plan - Stock Titan
Mizuho reiterates Outperform on BridgeBio stock on Russell move By Investing.com - Investing.com Canada
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Uncovering a Potential 51.92% Upside in the Biotechnology Sector - DirectorsTalk Interviews
Operating income of BridgeBio Pharma, Inc. – XETR:2CL - TradingView
Return on assets % of BridgeBio Pharma, Inc. – XETR:2CL - TradingView
Quick ratio of BridgeBio Pharma, Inc. – XETR:2CL - TradingView
Gross profit of BridgeBio Pharma, Inc. – XETR:2CL - TradingView
ETFs Investing in BridgeBio Pharma, Inc. Stocks - TradingView
BridgeBio Pharma, Inc. Balance Sheet – XETR:2CL - TradingView
BridgeBio Pharma, Inc. Cash Flow – XETR:2CL - TradingView
Biotech BridgeBio hands new recruits 31,428 stock units - Stock Titan
Brazil approves BridgeBio’s acoramidis for heart condition - Investing.com
Barclays Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $157 - Moomoo
BBIO: Attruby’s rapid growth and differentiated data anchor a pipeline poised for multiple rare disease launches - TradingView
BBIO: Attruby's rapid growth and differentiated data drive momentum as multiple rare disease launches near - TradingView
symbol__ Stock Quote Price and Forecast - CNN
BridgeBio (BBIO) Receives Buy Rating with $104 Target by Canacco - GuruFocus
CCORF Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $104 - Moomoo
Canaccord Genuity Group Initiates Coverage on BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat
Precision Trading with Bridgebio Pharma Inc. (BBIO) Risk Zones - Stock Traders Daily
BridgeBio Pharma director Ellis Andrea sells $4.2m in shares - Investing.com
Geode Capital Management LLC Purchases 502,582 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Citi Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $82 - Moomoo
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Exploring a Promising 54.93% Upside Potential - DirectorsTalk Interviews
Does FDA Priority Review for First LGMD Therapy Change The Bull Case For BridgeBio Pharma (BBIO)? - Yahoo Finance
BridgeBio gains as muscular dystrophy therapy gets FDA priority review - MSN
Farallon funds hold multi‑million share positions in BridgeBio (NASDAQ: BBIO) - Stock Titan
BBIO Maintained by Morgan Stanley -- Price Target Raised to $98. - GuruFocus
BBIO Maintained by Morgan Stanley -- Price Target Raised to $98.00 - GuruFocus
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $110 - Moomoo
BBIO Reiterates by HC Wainwright & Co. -- Price Target Maintained at $110 - GuruFocus
FDA accepts BridgeBio’s BBP-418 for priority review - The Pharma Letter
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cocrystal Pharma (COCP) - The Globe and Mail
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bridgebio Pharma Inc Stock (BBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Jun 05 '26 |
Sale |
67.88 |
40,000 |
2,715,077 |
515,686 |
| Kumar Neil | Chief Executive Officer |
Jun 04 '26 |
Sale |
67.46 |
40,000 |
2,698,211 |
535,686 |
| Kumar Neil | Chief Executive Officer |
May 21 '26 |
Sale |
69.44 |
26,103 |
1,812,522 |
243,327 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):